Wire · operational-macro
Psychedelic pioneer Compass files for FDA approval as rivals close in
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
Compass Pathways has submitted a New Drug Application (NDA) to the U.S. FDA for its synthetic psilocybin drug COMP360 targeting treatment-resistant depression. Competitors including Usona and Definium Therapeutics are progressing closely with their own psychedelic therapies, signalling an accelerating regulatory race in the psychedelic mental health treatment market.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 21 Oct 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
You are facing a fast-moving regulatory opportunity as multiple psychedelic therapies race to FDA approval. Acting now to position your mental health biotech for either partnership or differentiation could secure early access to this newly legitimised treatment class.
◆ Coverage
5 sources · first reported 21 Oct 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics